Visus Therapeutics Announces Positive Topline Clinical Data from Phase 2 VIVID Study of BRIMOCHOL for the Treatment of Presbyopia
Retrieved on:
Tuesday, November 30, 2021
Professional Services, Health, Venture Capital, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Patient, Visu, Visual acuity, Ageing, Safety, Population, Lens (anatomy), Headache, VIVID, Brimonidine, Presbyopia, Research, NYU, Instagram, FDA, Glaucoma, Iraj Zebardast, Therapy, LinkedIn, Prevalence, Toxicity, Quality of life, Pharmaceutical industry, Presbyopia, Visus Therapeutics, PRESBYOPIA, VISUS THERAPEUTICS
A minimum of 35% of subjects in the study met this same endpoint at nine hours in all three formulations.
Key Points:
- A minimum of 35% of subjects in the study met this same endpoint at nine hours in all three formulations.
- Based on these positive outcomes, the company plans to commence Phase 3 pivotal trials shortly.
- The successful completion of the VIVID study marks an important milestone for Visus Therapeutics, said Ben Bergo, co-founder and chief executive officer at Visus Therapeutics.
- We are pleased the VIVID study data exceeded our expectations, demonstrating a clear opportunity to commercialize long-acting miotic formulations.